Aktis Oncology Inc
AKTSHealthcare|Biotechnology|USA
$27.88
-0.54 (-1.90%)
Tangible Book
$9.16
About
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
Stock Price
+24.5%(1Y)
Pipeline Summary
2 total trials2
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 2
Active Trials (2)
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT07020117Urothelial Carcinoma Bladder
Phase 1Recruiting
Enrollment: 150 participants
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07581184Castration Resistant Metastatic Prostate Cancer
Phase 1Recruiting
Enrollment: 138 participants
BioScore
4.4/10
Cautious
Ownership
Recent Insider Trades
Czibere AkosSELL
2026-07-0850,000 shares @ $27.77
Ron-Bigger ShulamitSELL
2026-07-0850,000 shares @ $27.75
Kim Helen SusanBUY
2026-01-12835,000 shares @ $18
EcoR1 Capital, LLCBUY
2026-01-122,222,222 shares @ $18
MPM BIOVENTURES 2018, L.P.BUY
2026-01-121,112,777 shares @ $18
Recent News
2026-06-16 16:59:44
2026-06-16 10:30:58
Data last updated: Jul 13, 2026, 12:46 PM